Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_assertion description "[In this report, we explore the impact of the p38 activating, FDA-approved, blood brain barrier permeating compound celecoxib on SMN levels in vitro and in a mouse model of SMA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_assertion evidence source_evidence_literature NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_assertion SIO_000772 23656793 NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_assertion wasDerivedFrom befree-20140225 NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_assertion wasGeneratedBy ECO_0000203 NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.
- befree-20140225 importedOn "2014-02-25" NP882141.RA3J_YJVVrnG0y9BxOhGEjLpd5CJ3BJTeFFMJ1AvgfXko130_provenance.